Research graph
References from A multiparametric in vitro strategy for small molecule drug-induced liver injury risk mitigation in early drug development. Local targets link to admitted publications; unresolved targets remain external evidence.
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump
10.1002/hep.27206 · 2014 · External reference
Safety data and withdrawal of hepatotoxic drugs
10.1016/j.therap.2018.02.004 · 2021 · External reference
BDDCS applied to over 900 drugs
10.1208/s12248-011-9290-9 · 2011 · External reference
A large-scale human toxicogenomics resource for drug-induced liver injury prediction
10.1038/s41467-025-65690-3 · 2025 · External reference
Hyperparameter optimization: foundations, algorithms, best practices, and open challenges
10.1002/widm.1484 · 2023 · External reference
Random forests
10.1023/1010933404324 · 2001 · External reference
Post-acquisition analysis of untargeted accurate mass quadrupole time-of-flight MSE data for multiple collision-induced neutral losses and fragment ions of glutathione conjugates
10.1002/rcm.7062 · 2014 · External reference
Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study
10.1053/j.gastro.2015.03.006 · 2015 · External reference
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States
10.1053/j.gastro.2008.09.011 · 2008 · External reference
Measures of BSEP inhibition in vitro are not useful predictors of DILI
10.1093/toxsci/kfx284 · 2018 · External reference
Toward predictive models for drug-induced liver injury in humans: are we there yet?
10.2217/bmm.13.146 · 2014 · External reference
High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury
10.1002/hep.26208 · 2013 · External reference
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans
10.1016/j.drudis.2016.02.015 · 2016 · External reference
Improving confidence in the determination of free fraction for highly bound drugs using bidirectional equilibrium dialysis
10.1016/j.xphs.2018.10.011 · 2019 · External reference
Chapter sixteen analysis and interpretation of microplate-based oxygen consumption and pH data
10.1016/b978-0-12-801415-8.00016-3 · 2014 · External reference
Assessing bioenergetic function in response to oxidative stress by metabolic profiling
10.1016/j.freeradbiomed.2011.08.005 · 2011 · External reference
Performance assessment and economic analysis of a human liver-chip for predictive toxicology
10.1038/s43856-022-00209-1 · 2022 · External reference
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans
10.1093/toxsci/kft223 · 2014 · External reference
The vesicular transport assay: validated in vitro methods to study drug-mediated inhibition of canalicular efflux transporters ABCB11/BSEP and ABCC2/MRP2
10.1002/0471140856.tx2304s54 · 2012 · External reference
Drug-induced liver injury: a comprehensive review
10.1177/17562848231163410 · 2023 · External reference
Liabilities associated with the formation of “hard” electrophiles in reactive metabolite trapping screens
10.1021/acs.chemrestox.6b00332 · 2017 · External reference
Multiple compound-related adverse properties contribute to liver injury caused by endothelin receptor antagonists
10.1124/jpet.114.220491 · 2015 · External reference
Can bile salt export pump inhibition testing in drug discovery and development reduce liver injury risk? An international transporter consortium perspective
10.1002/cpt.1222 · 2018 · External reference
Drug–drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug–drug interaction prediction
10.1007/s11095-012-0724-6 · 2012 · External reference
Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals
10.1002/hep.22272 · 2008 · External reference
mlr3: a modern object-oriented machine learning framework in R
10.21105/joss.01903 · 2019 · External reference
Timing of new black box warnings and withdrawals for prescription medications
10.1001/jama.287.17.2215 · 2002 · External reference
Early drug-induced liver injury risk screening: “free,” as good as it gets
10.1093/toxsci/kfac054 · 2022 · External reference
An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making
10.1136/bmjopen-2013-004221 · 2014 · External reference
Toward quantitative models in safety assessment: a case study to show impact of dose–response inference on hERG inhibition models
10.3390/ijms24010635 · 2022 · External reference
Cyanide trapping of iminium ion reactive metabolites: implications for clinical hepatotoxicity
10.1021/acs.chemrestox.3c00402 · 2024 · External reference
Current nonclinical testing paradigm enables safe entry to first-in-human clinical trials: the IQ consortium nonclinical to clinical translational database
10.1016/j.taap.2017.09.006 · 2017 · External reference
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development
10.1093/toxsci/kft176 · 2013 · External reference
Evaluation of time-dependent cytochrome P450 inhibition in a high-throughput, automated assay: introducing a novel area under the curve shift approach
10.2174/187231212800229309 · 2012 · External reference
In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk
10.1007/s00204-020-02804-4 · 2020 · External reference
Concordance of the toxicity of pharmaceuticals in humans and in animals
10.1006/rtph.2000.1399 · 2000 · External reference
Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature
10.1186/s12916-016-0553-2 · 2016 · External reference
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
10.1007/s00204-017-2002-1 · 2017 · External reference
pROC: an open-source package for R and S + to analyze and compare ROC curves
10.1186/1471-2105-12-77 · 2011 · External reference
Industry perspective on nonclinical approaches for hepatotoxicity risk assessment: insights from two longitudinal surveys conducted in 2023 and 2017
10.1021/acs.chemrestox.5c00235 · 2025 · External reference
Minimizing DILI risk in drug discovery: a screening tool for drug candidates
10.1016/j.tiv.2015.09.019 · 2015 · External reference
LiverTox: an online information resource and a site for case report submission on drug-induced liver injury
10.1002/cld.388 · 2014 · External reference
Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays
10.1093/toxsci/kfv152 · 2015 · External reference
The generation, detection, and effects of reactive drug metabolites
10.1002/med.21273 · 2013 · External reference
Unresolved reference
2022 · External reference
Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues
10.21037/atm-2020-ubih-05 · 2021 · External reference
The liver toxicity knowledge base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury
10.1080/17474124.2018.1383154 · 2018 · External reference
A modified multiparametric assay using HepaRG cells for predicting the degree of drug-induced liver injury risk
10.1002/jat.3371 · 2017 · External reference
The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development
10.1007/s00204-020-02763-w · 2020 · External reference
Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models
10.1038/s41573-019-0048-x · 2020 · External reference
Predicting drug-induced liver injury with Bayesian machine learning
10.1021/acs.chemrestox.9b00264 · 2020 · External reference
Harmonised high throughput microsomal stability assay
10.1016/j.vascn.2016.10.006 · 2017 · External reference
Ranger : a fast implementation of random forests for high dimensional data in C++ and R
10.18637/jss.v077.i01 · 2017 · External reference
Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system
10.1007/s11095-004-9004-4 · 2005 · External reference
10.1007/978-1-0716-1542-3
10.1007/978-1-0716-1542-3 · 2021 · External reference
High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury
10.1124/dmd.113.056267 · 2014 · External reference
Strategies to mitigate the bioactivation of aryl amines
10.1021/acs.chemrestox.0c00138 · 2020 · External reference
